Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 587 Results
Considering the Future Impact of COVID on Health Spending
AcademyHealth and the National Pharmaceutical Council hosted a salon examining the impact of the pandemic on health spending and resulting challenges to our health care system.
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
Health Plan Enrollment May be Open, but Drug Coverage Is Still a Black Box for Many People
Most people choose coverage based mainly on the price – the health care premiums and deductibles. But a narrow focus on health care costs overlooks the overall quality of the health plan. Consumers…
Digging Deeper Into Health Spending Data
NPC looks at AHIP's annual “Your Health Care Dollar” analysis, providing proper context and data behind the numbers.
Are ACOs Optimizing Medication Use?
An article in JMCP revisits a 2014 NPC study that surveyed Accountable Care Organizations (ACOs) readiness to optimize medication use. The Reflection article summarizes changes to the ACO policy…
How Can Payers Advance Patient-reported Measures in Oncology, and Why Should We Care?
A peer-reviewed study describes the current state of patient-reported measures and patient-reported performance measures in oncology, the barriers to implementation, and actionable recommendations…
Tackling the Real Drivers of Health Spending
A new Kaiser Family Foundation analysis examined 2018 health spending per capita in the United States compared to economically similar countries. The researchers found that outpatient and inpatient…
Supporting Value-Based Purchasing Through Changes in Medicaid Best Price
In a recent column for PharmaBoardroom, Michael Ciarametaro, vice president for research at the National Pharmaceutical Council, elaborated on the ways in which MBP presents a barrier to creative…
Why the Benefits of Medicines – Not Just Costs – Must Be a Part of the Conversation
NPC's Dr. Dubois discusses a Health Affairs article identifying public health efforts and pharmaceuticals as leading drivers impacting increased life expectancy in the U.S. between 1990 and 2015.
Building on NPC’s Commitment to Sound Health Policy Research and Evidence-based Dialogue
As the interim leader of NPC, Dr. Robert Dubois is focused on two priorities: continuing to leverage NPC's evidence-based research, partnerships, and education, and preparing for future policy…
IVI's Jennifer Bright on Value Assessment and Transparency
In an interview, Innovation and Value Initiative Executive Director Jennifer Bright discusses how her organization has been advancing value assessment practice and the key priorities to make the…
It’s Time to Talk About COVID-19 Prices: Webinar Recap
A summary with video clips from the robust discussion about the societal value and pricing of potential COVID-19 treatments and incentives for current and post-pandemic medical innovation.
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft…
Ensuring Care for Vulnerable Populations
NPC President and CEO Dan Leonard discusses how the COVID-19 pandemic has highlighted the persistence of barriers that hamper access to health care for many, especially those in vulnerable…
Addressing Low-Value Care in the Time of COVID-19
The COVID-19 pandemic has had an enormous economic impact that is being felt across our communities, businesses and the overall health care system. It has placed a larger spotlight on the challenges…
NPC Comments on CMS Best Price and Barriers to Value-Based Arrangements
NPC outlines how Medicaid Best Price poses a barrier to implementing value-based arrangements and hinders innovation in payment and delivery systems, which can make it difficult for patients to…